WO1993021220A1 - Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection - Google Patents
Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection Download PDFInfo
- Publication number
- WO1993021220A1 WO1993021220A1 PCT/AU1993/000131 AU9300131W WO9321220A1 WO 1993021220 A1 WO1993021220 A1 WO 1993021220A1 AU 9300131 W AU9300131 W AU 9300131W WO 9321220 A1 WO9321220 A1 WO 9321220A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- synthetic peptide
- protein
- amino acid
- cell epitope
- antibody
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 185
- 229960005486 vaccine Drugs 0.000 title claims abstract description 24
- 206010061372 Streptococcal infection Diseases 0.000 title claims abstract description 10
- 238000003745 diagnosis Methods 0.000 title claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 title description 104
- 101710085938 Matrix protein Proteins 0.000 claims abstract description 58
- 101710127721 Membrane protein Proteins 0.000 claims abstract description 58
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 33
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 31
- 210000005003 heart tissue Anatomy 0.000 claims abstract description 25
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims description 10
- 238000007792 addition Methods 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000004727 humoral immunity Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 210000004027 cell Anatomy 0.000 description 25
- 102000003505 Myosin Human genes 0.000 description 23
- 108060008487 Myosin Proteins 0.000 description 23
- 201000003068 rheumatic fever Diseases 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 239000000284 extract Substances 0.000 description 13
- -1 thiol compounds Chemical class 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 208000019622 heart disease Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 230000002788 anti-peptide Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000009260 cross reactivity Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 208000004124 rheumatic heart disease Diseases 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010008748 Chorea Diseases 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000027522 Sydenham chorea Diseases 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 102000005937 Tropomyosin Human genes 0.000 description 3
- 108010030743 Tropomyosin Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 230000021235 carbamoylation Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- KFDPCYZHENQOBV-UHFFFAOYSA-N 2-(bromomethyl)-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1CBr KFDPCYZHENQOBV-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- JAJQQUQHMLWDFB-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-5-phenylpentanoate Chemical compound OC(=O)CC(O)C(N)CC1=CC=CC=C1 JAJQQUQHMLWDFB-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 150000007930 O-acyl isoureas Chemical class 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- UATJOMSPNYCXIX-UHFFFAOYSA-N Trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UATJOMSPNYCXIX-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- AWGTVRDHKJQFAX-UHFFFAOYSA-M chloro(phenyl)mercury Chemical compound Cl[Hg]C1=CC=CC=C1 AWGTVRDHKJQFAX-UHFFFAOYSA-M 0.000 description 1
- VIMWCINSBRXAQH-UHFFFAOYSA-M chloro-(2-hydroxy-5-nitrophenyl)mercury Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[Hg]Cl VIMWCINSBRXAQH-UHFFFAOYSA-M 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- SJFKGZZCMREBQH-UHFFFAOYSA-N methyl ethanimidate Chemical compound COC(C)=N SJFKGZZCMREBQH-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates generally to vaccines and diagnostic reagents suitable for use against streptococcal infection. More particularly, the present invention relates to synthetic peptides based on the M protein of streptococci and carrying one or more B and/or T cell epitopes. Group A streptococci are responsible for many suppurative infections, but the etiologies of two-non-suppurative inflammatory conditions - rheumatic fever and its complications, and acute glomerulonephritis - are not well understood.
- Acute rheumatic fever follows a throat infection with certain serotypes of group A ⁇ -hemolytic streptococci (Kaplan et al., 1989).
- This disease and the recurrences which can follow further streptococcal throat infections, expresses its most serious pathology in the heart. It has been suggested that the disease represents an autoimmune illness initiated as a result of cross-reactivity between the M protein of streptococci and cardiac tissue (Cunningham and Russell, 1983; Cunningham et al., 1986; 1988; Dale and Beachey, 1986;
- one aspect of the present invention provides a synthetic peptide comprising at least one B cell epitope from the carboxyterminus of M protein of Group A ⁇ -hemolytic streptococci wherein an antibody reactive to the B cell epitope is only minimally reactive to human heart tissue.
- Another aspect of the present invention is directed to a synthetic peptide comprising at least one B cell epitope from the carboxyterminus of M protein of Group A hemolytic streptococci and at least one T cell epitope, wherein an antibody reactive to the B cell epitope is only minimally reactive to human heart tissue.
- the T cell epitope is also from the carboxyterminus of M protein or may be part of an extraneous or fusion molecule with the synthetic peptide.
- synthetic extends to recombinant and chemically synthesised molecules as well as biologically pure naturally occurring molecules.
- minimally reactive is meant that there is less than 35%, preferably less than 25%, more preferably less than 15%, even more preferably less than 5% and most preferably 0-2% binding of the antibody to heart tissue compared to the B cell epitope or the synthetic peptide.
- peptide is used in a general sense to cover molecules ranging from a few amino acid residues to several hundred amino acid residues.
- peptide is considered herein to cover a polypeptide.
- the peptides of the present invention are henceforth referred to as "M peptides" for the M protein of streptococci.
- the M peptides of the present invention do not extend to the full length M protein.
- the M peptides of the present invention may comprise an amino acid sequence exactly corresponding to a sequence in a region of the naturally occurring carboxyterminus of M protein or may contain single or multiple amino acid substitutions, deletions and/or additions to the naturally occurring sequence.
- the carboxyterminus is construed herein in its most general sense and extends from amino acid residues 270 to 492, more particularly 300 to 492 and most particularly 337 to 492 of the type 5 M protein.
- the M peptides contemplated herein may be chemically synthesized such as by solid phase peptide synthesis or may be prepared by subjecting the M protein to hydrolysis or other chemically disruptive processes to produce fragments of the molecule.
- the peptides can be made by in vitro or in vivo recombinant DNA synthesis. In this case, the peptides may need to be synthesised in combination with other proteins and then subsequently isolated by chemical cleavage or alternatively the peptides or polyvalent peptides may be synthesised in multiple repeat units.
- multiple epitope peptides or polyvalent peptides can also be prepared according to Tarn (1988). The selection of a method of producing the subject peptides will depend on factors such as the required type, quantity and purity of the peptides as well as ease of production and convenience.
- M peptides in vivo may first require their chemical modification since the peptides themselves may not have a sufficiently long serum and/or tissue half-life. Chemical modification of the subject peptides may also be important to improve their antigenicity including the ability for certain regions of the peptides to act as B and/or T cell epitopes. Such chemically modified M peptides are referred to herein as "analogues".
- analogues extends to any functional chemical or recombinant equivalent of the M peptides of the present invention characterised by their possession of at least one B cell epitope from the M protein of Group A ⁇ -hemolytic streptococci and wherein an antibody reactive to the B cell epitope is only minimally reactive with human heart tissue.
- analogue is also used herein to extend to any amino acid derivative of the peptides as described above.
- Analogues of M peptides contemplated herein include, but are not limited to, modifications to side chains, incorporation of unnatural amino acids and/or their derivatives during peptide synthesis and the use of crosslinkers and other methods which impose conformational constraints on the peptides or their analogues.
- side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6, trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5'-phosphate followed by reduction with NaBH 4
- modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6, trinitrobenzene sulphonic acid (TNBS); acylation of amino
- the guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.
- the carboxyl group may be modified by carbodi ⁇ mide activation via O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.
- Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.
- Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides.
- Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.
- Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.
- Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and /or D-isomers of amino acids.
- peptides can be conformationally constrained by, for example, incorporation of C ⁇ and N ⁇ -methylamino acids, introduction of double bonds between C ⁇ and C ⁇ atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.
- the present invention extends to peptides and polypeptides and amino acid and/or chemical analogues thereof corresponding to one or more regions of the M protein acting as at least one B cell epitope and which may also contain at least one T cell epitope as defined above.
- the preferred M peptides of the present invention include residues
- the M peptides are defined by the following amino acid sequences which corresponds to peptide 145 in Table 1:
- the present invention further contemplates a method for vaccinating a human subject against streptococci infection comprising administering to said subject a humoral immunity developing effective amount of a peptide comprising at least one B cell epitope from the M protein of Group A hemolytic streptococci and at least one T cell epitope wherein an antibody reactive with the B cell epitope is only minimally reactive with heart tissue for a time and under conditions sufficient for said immunity to develop or at least partially develop.
- a peptide has the same meaning as set forth above and the T cell epitope may or may not be from the M protein carboxyterminus although, in a preferred embodiment, it is located on the M peptide.
- the T cell epitope is separate to the M peptide and may, for example, be part of an adjuvant, such as Alum.
- this aspect of the present invention can be accomplished by a vaccine composition.
- another aspect of the present invention contemplates a vaccine useful in the development of humoral immunity to M protein but minimally cross reactive with heart tissue said vaccine comprising a peptide carrying at least one B cell epitope from the M protein and at least one T cell epitope wherein an antibody reactive with said B cell epitope is only minimally reactive with heart tissue and said vaccine further comprising one or more
- the vaccine may contain a single peptide type or a range of peptides covering different or similar epitopes.
- a single polypeptide may be provided with multiple epitopes.
- the latter type of vaccine is referred to as a polyvalent vaccine.
- the formation of vaccines is generally known in the art and reference can conveniently be made to Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, Pennsylvania, USA.
- the present invention contemplates a pharmaceutical composition or vaccine comprising a humoral immunity developing effective amount of M peptide or its derivatives, analogues or homologues and /or combinations thereof including other active molecules and one or more pharmaceutically acceptable carriers and /or diluents.
- compositions comprising the M peptide are contemplated herein to exhibit excellent therapeutic activity, for example, in the development of antibodies to M protein of streptococci but said antibodies being only minimally reactive with heart tissue when administered in amount which depends on the particular case. For example, from about 0.5 ug to about 20 mg per kilogram of body weight per day may be administered. Dosage regime may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be
- the active compound may be administered in a convenient manner such as by the oral, intravenous (where water soluble), intramuscular, subcutaneous, intranasal, intradermal or suppository routes or implanting (eg using slow release molecules).
- the active ingredients which comprise an M peptide may be required to be coated in a material to protect said ingredients from the action of enzymes, acids and other natural conditions which may inactivate said ingredients.
- the low l ⁇ pophilicity of the M peptides will allow them to be destroyed in the gastrointestinal tract by enzymes capable of cleaving peptide bonds and in the stomach by acid hydrolysis.
- M peptides may be administered in an adjuvant, co-administered with enzyme inhibitors or in liposomes.
- Adjuvant is used in its broadest sense and includes any immune stimulating compound such as interferon.
- Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether.
- Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol.
- Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes.
- the active compounds may also be administered parenterally or
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- sterile aqueous solutions where water soluble
- dispersions sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- the proper fluidity can be maintained, for example, by the use of a coating such as licithin, by the maintenance of the required particle size in the case of dispersion and by the use of superfactants.
- the preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thirmerosal and the like.
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
- the active, compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
- the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound.
- compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit.
- the amount of active compound in such therapeutically useful compositions in such that a suitable dosage will be obtained.
- Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 ug and 2000 mg of active compound.
- the tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalclum phosphate; a disintegrating agent such as corn starch, potato starch, algin ⁇ c acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring.
- a binder such as gum tragacanth, acacia, corn starch or gelatin
- excipients such as dicalclum phosphate
- a disintegrating agent such as corn starch, potato starch, algin ⁇ c acid and the like
- a lubricant such as magnesium stearate
- a sweetening agent such as sucrose, lactose or saccharin may be added or a flavouring agent such as pepper
- tablets, pills, or capsules may be coated with shellac, sugar or both.
- a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour.
- any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
- the active compound may be incorporated into sustained-release preparations and formulations.
- pharmaceutically acceptable carrier and /or diluent includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
- solvents dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
- the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is
- Supplementary active ingredients can also be incorporated into the compositions.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a
- novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.
- the principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore disclosed.
- a unit dosage form can, for example, contain the principal active compound in amounts ranging from 0.5 ⁇ g to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.5 ⁇ g to about 2000 mg/ml of carrier.
- the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
- Still another aspect of the present invention is directed to antibodies to the M peptides.
- Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to the M protein or may be specifically raised to the M peptides. In the case of the latter, the peptides may need first to be associated with a carrier molecule.
- the antibodies and/or M peptides of the present invention are particularly useful for immunotherapy and vaccination and may also be used as a diagnostic tool for infection or for monitoring the progress of a vaccination or therapeutic mita.
- the M peptides can be used to screen for naturally occurring antibodies to M protein.
- specific antibodies can be used to screen for M protein.
- Techniques for such assays are well known in the art and include, for example, sandwich assays and ELIZA.
- the M peptides are particularly useful in screening for antibodies to M protein and, hence, provide a diagnostic protocol for detecting streptococcal infection.
- biological samples such as blood serum, sputum, tissue and tissue extracts can be directly screened for M protein using antibodies raised to the M peptides.
- a method for the diagnosis of streptococcal infection in a subject comprising contacting a biological sample from said subject with an antibody binding effective amount of an M peptide for a time and under conditions sufficient for an antibody-M peptide complex to form, and then detecting said complex.
- M protein antibodies in a patient's blood serum, tissue, tissue extract or other bodily fluid, can be detected using a wide range of
- immunoassay techniques such as those described in US Patent Nos. 4,016,043, 4,424,279 and 4,018,653. This includes both single-site and two-site, or
- Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention.
- the results may either be qualitative, by simple observation of the visible signal or may be quantitated by comparing with a control sample containing known amounts of hapten.
- Variations of the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody, or a reverse assay in which the labelled antibody and sample to be tested are first combined, incubated and then added simultaneously to the bound antibody.
- the solid substrate is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
- the solid supports may be in. the form of tubes, beads, discs or microplates, or any other surface suitable for conducting an immunoassay.
- the binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing the molecule to the insoluble carrier.
- reporter molecule is meant a molecule which, by its chemical nature, profices an analytical identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative.
- the most commonly used reporter molecule in this type of assay re either enzymes, fluorophores or radionuclide containing molecules (i.e. rad ⁇ oisotopes).
- an enzyme is conjugated to the second antibody, generally by means of
- the substrates to be used with the specific enzymes are generally chosen for the production,upon hydrolysis by the corresponding enzyme, of a detectable colour change. It is also possible to employ fluorogenic substrates, which yield a fluorescent product.
- fluorescent compounds such as fluorescein and rhodamine
- fluorescent compounds may be chemically coupled to antibodies without altering their binding capacity.
- the fluorochrome-labelled antibody When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope.
- the fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex.
- the fluorescence observed indicates the presence of the hapten of interest, ⁇ nmunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method.
- other reporter molecules such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed. It will be readily apparent to the skilled technician how to vary the procedure to suit the required purpose. It will also be apparent that the foregoing can be used to label M peptides and to use same directly in the detection of M protein antibodies.
- Figure 1 is a graphical representation showing the proliferative response of lymph node cells from B10(A,E), B10.D2(B,F), B10.BR(C,G) and
- FIG. 2 is a photographic representation of an immunoblot of porcine heart myosin (lane 1), HCl-extract M protein (lane 2) and human heart tissue protein (lane 3).
- Membranes were reacted against anti-porcine heart myosin antisera (A); anti-M-5 cell extract antisera (B); normal mouse serum (C); B10.BR anti-peptide 145 antisera (D); B10.BR anti-peptide 146 antisera (E); B10.D2 anti-peptide 149 sera (F); BIO anti-peptide 150 antisera (G); B10.BR antipeptide 151 antisera (H) and B10.S(7R) anti-peptide 151 antisera (1).
- Relative molecular masses x10 -3 ) are listed at the left of the Figure.
- Figure 3 is a graphical representation showing mean positive optical density readings of ELISA assays of serum antibodies from (A) Caucasian and (B) minority subjects against individual peptides. See Example 2 for
- Streptococcal M-5 protein extract (Rotta, et al. 1980).
- M-5 group A streptococci were cultured in 80 ml Todd-Hewitt broth with 20% v/v fetal calf serum, incubated at 37C for 16 hours. Cells were centrifuged and washed (X3) with sterile PBS pH 7.4 and resuspended in HCl pH 2. The suspension was then boiled for 10 minutes in water bath. The pH was adjusted to 7.0 by NaOH and centrifuged at 3000 rpm for 10 minutes, the supernatant was isolated and checked for sterility by dropping on blood agar plate.
- Porcine heart myosin and tropomyosin were purchased from Sigma Chemical Co.
- Human heart atrial tissue was derived from surgical specimens and were cut into small pieces and macerated in an homogenizer with cold PBS pH 7.4, centrifuged, supernatant were kept at -20C until used. Pellets were suspended in SDS-PAGE sample buffer and boiled for 5 minutes, centrifuged, and supernatants were kept at 4C for running SDS-PAGE.
- Human heart pericard ⁇ al tissue was derived from surgical specimens and macerated in cold PBS pH 7.4 and centrifuged at 3000 rpm; the supernatant was isolated and kept at -20C until used.
- Peptides were administered subcutaneously at the tail base (either in pools of 6 or individually) to H-2 congenic mice on the B10 background [B10(H2 b ); B10.D2(H2 d ); B10. BR(H-2 k ); B10.S(7R)(H-2 S )], with each mouse receiving 30 ⁇ g of peptide emulsified in complete Freund's adjuvant (CFA) (Difco).
- CFA complete Freund's adjuvant
- lymph node cells were then plated in quardruplicate at 4 ⁇ l0 5 per well in flat-bottomed microtitre plates in MEM medium containing 2% v/v heat inactivated normal mouse serum, 5 ⁇ 10 - 5 M 2-mercaptoethanol, 20 ⁇ g gentamicin and antigen (at various concentrations).
- the plates were placed in a humidified 5% v/v CO 2 /air environment at 37C for 4 days and then each well was pulsed with 1 ⁇ Ci 3 [H]thymidine for 16 hrs. Incorporation of label was measured by liquid scintillation spectroscopy using a ⁇ -plate counter (LKB).
- a "Stimulation Index" (SI) was defined as: ⁇ cpm (in the presence of
- mice were immunized subcutaneously with 30 ⁇ g of peptide emulsified in CFA. Mice were given subsequent booster injections at intervals of 10 days with 30 ⁇ g peptide dissolved in PBS for 3 boosters. Prior to boost, mice were bled via the tail artery and sera prepared and kept at -20C until used.
- Antigen was diluted to 5 ⁇ g/ml in carbonate-bicarbonate buffer (pH9.6) and coated onto polyvinyl chloride microplates (Flow Laboratory) in a volume of 100 ⁇ l per well overnight at room temperature. The antigen was then removed and the wells blocked with 200 ⁇ l of 2% w/v bovine serum albumin (BSA) for 1 hr at 37C. Plates were then washed 5 times with PBS-Tween 20 buffer.
- BSA bovine serum albumin
- Serum dilutions were prepared in 0.5% w/v BSA PBS-Tween 20 (BSA-PBS-T) buffer and incubated for 1 hr at 37C. The plates were then washed and peroxidase-conjugated goat-anti-mouse IgG (Tago Inc.) was then added at a dilution of 1:4000 in BSA-PBS-T for 1 hr at 37C. After further washing, ABTS substrate in citric acid and H 2 O 2 was applied and incubated for 30 mins, the optical density was measured at 405 nm in an ELISA reader (Multiscan, Flow Laboratories). The lowest dilution that gave an OD of greater than 3SD above the mean OD of control wells (containing normal mouse serum at the same dilution) was defined as the titre. ELISA for determining human antibodies.
- the blot was blocked with 3% w/v skim milk with 0.05% v/v Tween 20 overnight at 4C.
- the membrane was then added to 1:100 dilution of mouse serum containing putative antibodies for 1 hr at 37C, then 1:1000 dilution of peroxidase conjugated goat-anti-mouse IgG in 3% w/v skim milk without Tween 20 for 1 hr at 37C.
- Membranes were washed 5 times with PBS between steps.
- the antigen bands were observed after the addition of substrate (4-chloro-1-naphthol in methanol and H 2 O 2 ) for 10 min. The reaction was stopped by washing with distilled water. Bactericidal assay.
- M-5 group A streptococci were cultured overnight in 1 ml Todd-Hewitt broth at 37C, centrifuged and resuspended in 10 ml skim milk broth and stored at -70C until used. Before the assay, the bacteria were thawed and diluted to 10 -5 dilution in sterile normal saline. Fifty ⁇ l of the bacterial dilution was then mixed with 50 ⁇ l of mouse serum and 400 ⁇ l of normal heparinized human blood was added. The mixture was then incubated with end over end rotation at 37C for 3 hrs, and 50 ⁇ l of the mixture was diluted and spread onto blood agar plates and colonies counted after 24-48 hrs of incubation. The percentage of bacteria killed was determined by counting the number of colonies growing following incubation with test sera and comparing this with the number of colonies growing following incubation in control sera.
- mice which differ only at their MHC loci (H-2) were immunized at the tail base with groups of pooled peptides (6 peptides per pool) which overlapped the carboxylterminal conserved half of the M protein and the aminoterminal variants (Table 1, peptides 145-162). Draining lymph node cells were then challenged in v ⁇ rawith individual peptides. This protocol is designed to optimize the screening procedure for T cell epitopes. Six mice were used for each immunization and the experiments were each performed 2 or 3 times for each strain/pool combination ( Figure 1 A,B,C,D). A number of possible T cell epitopes were thus identified for each strain.
- mice were immunized with peptides from the M protein and draining lymph node cells stimulated in vitro with porcine heart myosin as well as peptides representing human heart myosin and human skeletal muscle myosin (chosen because of their sequence homology with M protein as shown in Table 2). The results are shown in Table 3.
- mice were immunized subcutaneously with the individual peptides emulsified in CFA, boosted with aqueous peptide (X3), and serum analysed for the presence of peptide-specific antibodies. Many peptides stimulated antibody production indicating that many of the proiiferative T cell epitopes were also helper epitopes (Table 4).
- mice were immunized with individual peptides, and then T cells and antibodies tested for reactivity to overlapping peptides (overlap of 10 amino acids).
- Table 5 lists the various stimulation indices and ELISA titres for the immunodominant epitopes. In most cases, T and B cell epitopes appeared to map to similar regions of the peptides. With respect to peptide 149 antibodies from B10JD2 mice reacted well with both peptides 148 and 149, whereas peptide 149-specific T cells respond well to peptide 149, but not at all to peptide 148.
- mice were immunized with various peptides and the results of pooled or individual sera are given in Table 6 for porcine myosin-reactive antisera. Following this,
- mice were immunized and boosted with either peptides 149 or 151- the peptides most strongly associated with induction of anti-myosin responses in Table 6.
- Tables 6 and 7 even though these mice are inbred H-2 congenic animals, differences were noted between individual animals in their ability to generate anti-myosin antibodies, although all animals in Table 7 produced antipeptide antibodies.
- antibodies to peptides 145, 146, 149, 150, and 151 reacted with porcine heart myosin (Fig. 2 D-I).
- Antibodies to the conserved peptides as well as antibodies to the type-specific aminoterminal B cell epitopes were tested for their ability to kill serotype 5 group A streptococci in a bactericidal assay (Table 8). As previously described, antibodies to peptide 160 (aminoterminal epitope from type M-5) were associated with significant killing (Beachey et al, 1988); however, the inventors were able to reproducibly show that antibodies to peptides 145.
- ARFA Abrared rheumatic fever
- HEARTA Abrares having other (non-rheumatic) forms of heart disease
- HEARTC Caucasians having other (non-rheumatic) forms of heart disease
- Overlapping synthetic peptides spanning the conserved region of the M 5 protein were produced as described in Example 1.
- Human heart pericardial tissue was derived from surgical specimens as described in Example 1.
- Peripheral blood mononuclear cells were prepared by layering blood diluted in an equal volume of MEM over Ficoll-paque, centrifuging at 400 g for 25 min, and collecting the buoyant cells. Cells were washed, counted and added to round-bottomed microtiter wells at a concentration of 200,000 cells per well in MEM medium containing 10% v/v normal human serum, and gentamicin (20 ⁇ g/ml). Some wells contained peptide at optimal concentration (30 ⁇ g/well), whereas other wells without peptide were used as control wells.
- the method is generally as described in Good el al (1987).
- the peripheral blood lymphocytes from a donor (GL) were stimulated with 150 ⁇ g/ml of HCl extracted M protein in vitro and incubated at 37 oC in 5% v/v CO 2 atmosphere for 6 days. Aliquols of 30 units/ml of r-lL-2 was then added for 7-10 days and the cells were stimulated again with the same amount of peptide with 4 ⁇ 10 6 autologous PBMC without IL-2. After further expansion with IL-2 for 10-14 days, the lines were assayed.
- the method is generally as described in Doolan el aL (1991), Autologous PBM were stimulated with 3 ⁇ g/ml PHA in MEM supplemented with 10% v/v normal human serum for 3 days and 30 U/ml of IL-2. The PHA blasts were rested for 3 days then washed 3 times and labelled for 1 hr at 37 °C with 100 ⁇ Ci of 51 Cr, with or without 10 ⁇ g/ml of peptide 145, 146 or M protein.
- carboxylterminal region of the M protein were used to define B and T cell epitopes in Indiana donors comprising patients with histories of RF, RHD, other heart diseases (mainly ischaemic) and normal controls, and Caucasian donors comprising those with past histories of RF, other heart diseases (mainly ischaemic) and normal controls.
- T cell epitopes were defined using the lymphoproliferation assay. Initially, the reactivity to the peptides of cord blood lymphocytes of 17 healthy Caucasian neonates born from healthy mothers was tested. Since the highest stimulation index recorded was 5, this value was used as a cutoff for the proliferation studies for the adult subjects. Amongst Caucasians, individuals with past history of RF responded more frequently than individuals with no history of RF. The peptide most frequently recognized by this group was peptide 145 (25% of individuals). Surprisingly, however, T cells from 10-25% of individuals with other heart diseases (predominantly ischaemic heart disease) also responded to many peptides.
- T cells from patients with past histories of RF or RHD responded more frequently than T cells from normal control subjects or patients with other heart diseases.
- Peptides 145, 147, 152 and 157 were recognized by >20% of the population studied.
- Within the European group there was no significant difference in the peptide-specific T cell responses of patients with established RHD and those with past or present histories of RF.
- T cell lines specific for peptides 145 and 146, and for an acid extract of serotype 5 M protein were generated.
- the donor was a normal Caucasian individual with no history of heart disease. All lines responded to both peptides 145 and 146, including the M protein-specific line which responded to both the peptides and to the M protein extract at equivalent levels. This confirms that in this individual, the T cell epitope is represented by the overlapping segment of these peptides (AKKQVEKALE), and that this epitope is the dominant epitope within the protein.
Abstract
The present invention provides a synthetic peptide comprising at least on B cell epitope from the carboxyterminus of M protein of Group A ß-hemolitic streptococci wherein an antibody reactive to the B cell epitope is only minimally reactive to human heart tissue. The synthetic peptide may also contain a T cell epitope. The present invention further comtemplates a vaccine comprising the synthetic peptide and a method for vaccinating human subjects against streptococcal infection.
Description
SYNTHETIC PEPTIDES USEFUL IN A VACCINE AGAINST AND IN THE DIAGNOSIS OF STREPTOCOCCAL INFECTION The present invention relates generally to vaccines and diagnostic reagents suitable for use against streptococcal infection. More particularly, the present invention relates to synthetic peptides based on the M protein of streptococci and carrying one or more B and/or T cell epitopes. Group A streptococci are responsible for many suppurative infections, but the etiologies of two-non-suppurative inflammatory conditions - rheumatic fever and its complications, and acute glomerulonephritis - are not well understood. Acute rheumatic fever follows a throat infection with certain serotypes of group A β-hemolytic streptococci (Kaplan et al., 1989). This disease, and the recurrences which can follow further streptococcal throat infections, expresses its most serious pathology in the heart. It has been suggested that the disease represents an autoimmune illness initiated as a result of cross-reactivity between the M protein of streptococci and cardiac tissue (Cunningham and Russell, 1983; Cunningham et al., 1986; 1988; Dale and Beachey, 1986;
Ayakawa et al. 1988; Fenderson et al., 1989). Immunity to gruop A β-hemolytic streptococci is nevertheless indicated by antibodies to the M protein. However, a subunit vaccine to prevent rheumatic fever based on the M protein has hithertofore not been possible due to the presence of potentially
deleterious epitopes, i.e. those cross-reactive with heart tissue and to the fact that the aminoterminal half of the protein is highly variable. There is a need, therefore, to develop a subunit vaccine that contains epitopes which are targets of neutralising antibodies, but which do not contain heart cross-reactive epitopes. In work leading up to the present invention, the immunogenicity of epitopes located in the highly conserved carboxyterminus of the protein were examined to locate T cell epitopes and/or conserved B cell epitopes.
In accordance with the present invention, peptides have been synthesised carrying epitopes reactive to antibodies to M protein but only minimally reactive, if at all, to human heart tissue. Such peptides will be useful in the development of a vaccine against streptococcal infection and in particular rheumatic fever and in developing a range of diagnostic reagents for
streptococcal infection.
Accordingly, one aspect of the present invention provides a synthetic peptide comprising at least one B cell epitope from the carboxyterminus of M protein of Group A β-hemolytic streptococci wherein an antibody reactive to the B cell epitope is only minimally reactive to human heart tissue.
Another aspect of the present invention is directed to a synthetic peptide comprising at least one B cell epitope from the carboxyterminus of M protein of Group A hemolytic streptococci and at least one T cell epitope, wherein an antibody reactive to the B cell epitope is only minimally reactive to human heart tissue.
In one embodiment, the T cell epitope is also from the carboxyterminus of M protein or may be part of an extraneous or fusion molecule with the synthetic peptide. The term "synthetic" extends to recombinant and chemically synthesised molecules as well as biologically pure naturally occurring molecules. By "minimally reactive" is meant that there is less than 35%, preferably less than 25%, more preferably less than 15%, even more preferably less than 5% and most preferably 0-2% binding of the antibody to heart tissue compared to the B cell epitope or the synthetic peptide. The term "peptide" is used in a general sense to cover molecules ranging from a few amino acid residues to several hundred amino acid residues.
Furthermore, the term "peptide" is considered herein to cover a polypeptide.
The peptides of the present invention are henceforth referred to as "M peptides" for the M protein of streptococci. The M peptides of the present invention do not extend to the full length M protein. The M peptides of the present invention may comprise an amino acid sequence exactly corresponding to a sequence in a region of the naturally occurring carboxyterminus of M protein or may contain single or multiple amino acid substitutions, deletions and/or additions to the naturally occurring sequence. The carboxyterminus is construed herein in its most general sense and extends from amino acid residues 270 to 492, more particularly 300 to 492 and most particularly 337 to 492 of the type 5 M protein.
The M peptides contemplated herein may be chemically synthesized such as by solid phase peptide synthesis or may be prepared by subjecting the M protein to hydrolysis or other chemically disruptive processes to produce fragments of the molecule. Alternatively, the peptides can be made by in vitro or in vivo recombinant DNA synthesis. In this case, the peptides may need to be synthesised in combination with other proteins and then subsequently isolated by chemical cleavage or alternatively the peptides or polyvalent peptides may be synthesised in multiple repeat units. Furthermore, multiple epitope peptides or polyvalent peptides can also be prepared according to Tarn (1988). The selection of a method of producing the subject peptides will depend on factors such as the required type, quantity and purity of the peptides as well as ease of production and convenience.
The use of these M peptides in vivo may first require their chemical modification since the peptides themselves may not have a sufficiently long serum and/or tissue half-life. Chemical modification of the subject peptides may also be important to improve their antigenicity including the ability for certain regions of the peptides to act as B and/or T cell epitopes. Such chemically modified M peptides are referred to herein as "analogues". The term "analogues" extends to any functional chemical or recombinant equivalent
of the M peptides of the present invention characterised by their possession of at least one B cell epitope from the M protein of Group A β-hemolytic streptococci and wherein an antibody reactive to the B cell epitope is only minimally reactive with human heart tissue. The term "analogue" is also used herein to extend to any amino acid derivative of the peptides as described above.
Analogues of M peptides contemplated herein include, but are not limited to, modifications to side chains, incorporation of unnatural amino acids and/or their derivatives during peptide synthesis and the use of crosslinkers and other methods which impose conformational constraints on the peptides or their analogues.
Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH4 amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6, trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5'-phosphate followed by reduction with NaBH4
The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.
The carboxyl group may be modified by carbodiϊmide activation via O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.
Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic
acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.
Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.
Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.
Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and /or D-isomers of amino acids.
Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having (CH2)n spacer groups with n = 1 to n = 6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of Cα and Nα-methylamino acids, introduction of double bonds between Cβ and Cβ atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain
and the N or C terminus.
The present invention, therefore, extends to peptides and polypeptides and amino acid and/or chemical analogues thereof corresponding to one or more regions of the M protein acting as at least one B cell epitope and which may also contain at least one T cell epitope as defined above.
The preferred M peptides of the present invention include residues
representing the conserved region of the M protein and in particular amino acid residues 337 to 492 of the type 5 M protein, including any derivatives or analogues thereof as contemplated above as well as multiple repeats and/or combinations from this region. However, all useful peptides from the carboxyterminus or variations thereof as hereinbefore defined, are
encompassed in the present invention. In a most preferred embodiment of the present invention, the M peptides are defined by the following amino acid sequences which corresponds to peptide 145 in Table 1:
LRRDLDASREAKKQVEKALE The present invention further contemplates a method for vaccinating a human subject against streptococci infection comprising administering to said subject a humoral immunity developing effective amount of a peptide comprising at least one B cell epitope from the M protein of Group A hemolytic streptococci and at least one T cell epitope wherein an antibody reactive with the B cell epitope is only minimally reactive with heart tissue for a time and under conditions sufficient for said immunity to develop or at least partially develop. Such a peptide has the same meaning as set forth above and the T cell epitope may or may not be from the M protein carboxyterminus although, in a preferred embodiment, it is located on the M peptide. In an alternative embodiment, the T cell epitope is separate to the M peptide and may, for example, be part of an adjuvant, such as Alum. Generally, this aspect of the present invention can be accomplished by a vaccine composition.
Accordingly, another aspect of the present invention contemplates a vaccine useful in the development of humoral immunity to M protein but minimally cross reactive with heart tissue said vaccine comprising a peptide carrying at least one B cell epitope from the M protein and at least one T cell epitope wherein an antibody reactive with said B cell epitope is only minimally reactive with heart tissue and said vaccine further comprising one or more
pharmaceutically acceptable carriers and/or diluents. Such an M peptide is as defined above. The vaccine may contain a single peptide type or a range of peptides covering different or similar epitopes. In addition, or alternatively, a single polypeptide may be provided with multiple epitopes. The latter type of vaccine is referred to as a polyvalent vaccine. The formation of vaccines is generally known in the art and reference can conveniently be made to Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, Pennsylvania, USA.
The present invention, therefore, contemplates a pharmaceutical composition or vaccine comprising a humoral immunity developing effective amount of M peptide or its derivatives, analogues or homologues and /or combinations thereof including other active molecules and one or more pharmaceutically acceptable carriers and /or diluents. The active ingredients of a
pharmaceutical composition comprising the M peptide are contemplated herein to exhibit excellent therapeutic activity, for example, in the development of antibodies to M protein of streptococci but said antibodies being only minimally reactive with heart tissue when administered in amount which depends on the particular case. For example, from about 0.5 ug to about 20 mg per kilogram of body weight per day may be administered. Dosage regime may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be
proportionally reduced as indicated by the exigencies of the therapeutic
situation. The active compound may be administered in a convenient manner such as by the oral, intravenous (where water soluble), intramuscular, subcutaneous, intranasal, intradermal or suppository routes or implanting (eg using slow release molecules). Depending on the route of administration, the active ingredients which comprise an M peptide may be required to be coated in a material to protect said ingredients from the action of enzymes, acids and other natural conditions which may inactivate said ingredients. For example, the low lϊpophilicity of the M peptides will allow them to be destroyed in the gastrointestinal tract by enzymes capable of cleaving peptide bonds and in the stomach by acid hydrolysis. In order to administer M peptides by other than parenteral administration, they will be coated by, or administered with, a material to prevent its inactivation. For example, M peptides may be administered in an adjuvant, co-administered with enzyme inhibitors or in liposomes. Adjuvant is used in its broadest sense and includes any immune stimulating compound such as interferon. Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes.
The active compounds may also be administered parenterally or
intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and
storage and must be preserved against the contaminating action of
microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as licithin, by the maintenance of the required particle size in the case of dispersion and by the use of superfactants. The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thirmerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
When the M peptides are suitably protected as described above, the active, compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of
ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions in such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 ug and 2000 mg of active compound.
The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalclum phosphate; a disintegrating agent such as corn starch, potato starch, alginϊc acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.
As used herein "pharmaceutically acceptable carrier and /or diluent" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the
art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is
contemplated. Supplementary active ingredients can also be incorporated into the compositions.
It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a
predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.
The principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore disclosed. A unit dosage form can, for example, contain the principal active compound in amounts ranging from 0.5 μg to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.5 μg to about 2000 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
Still another aspect of the present invention is directed to antibodies to the M peptides. Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to the M protein or may be specifically raised to the M peptides. In the case of the latter, the peptides
may need first to be associated with a carrier molecule. The antibodies and/or M peptides of the present invention are particularly useful for immunotherapy and vaccination and may also be used as a diagnostic tool for infection or for monitoring the progress of a vaccination or therapeutic regima.
For example, the M peptides can be used to screen for naturally occurring antibodies to M protein. Alternatively, specific antibodies can be used to screen for M protein. Techniques for such assays are well known in the art and include, for example, sandwich assays and ELIZA.
In accordance with this aspect of the present invention, the M peptides are particularly useful in screening for antibodies to M protein and, hence, provide a diagnostic protocol for detecting streptococcal infection. Alternatively, biological samples, such as blood serum, sputum, tissue and tissue extracts can be directly screened for M protein using antibodies raised to the M peptides.
Accordingly, there is provided a method for the diagnosis of streptococcal infection in a subject comprising contacting a biological sample from said subject with an antibody binding effective amount of an M peptide for a time and under conditions sufficient for an antibody-M peptide complex to form, and then detecting said complex.
The presence of M protein antibodies in a patient's blood serum, tissue, tissue extract or other bodily fluid, can be detected using a wide range of
immunoassay techniques such as those described in US Patent Nos. 4,016,043, 4,424,279 and 4,018,653. This includes both single-site and two-site, or
"sandwich", assays of the non-competitive types, as well as in the traditional competitive binding assays. Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, ϊn a typical forward assay, an M peptide is immobilised onto a solid substrate to form a
first complex and the sample to be tested for M protein antibody brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an M-peptide-antibody secondary complex. An anti-immunoglobulin antibody, labelled with a reporter molecule capable of producing a detectable signal, is then added and
incubated, allowing time sufficient for the formation of a tertiary complex of M peptide-antibody-labelled antibody. Any unreacted material is washed away, and the presence of the first antibody is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal or may be quantitated by comparing with a control sample containing known amounts of hapten. Variations of the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody, or a reverse assay in which the labelled antibody and sample to be tested are first combined, incubated and then added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, and the possibility of minor variations will be readily apparent. A similar approach is adopted to detect M protein. The antibodies used above may be monoclonal or
polyclonal.
The solid substrate is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in. the form of tubes, beads, discs or microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing the molecule to the insoluble carrier.
By "reporter molecule", as used in the present specification, is meant a molecule which, by its chemical nature, profices an analytical identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecule
in this type of assay re either enzymes, fluorophores or radionuclide containing molecules (i.e. radϊoisotopes). In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of
glutaraldehyde or periodate. As will be readily recognised, however, a wide variety of different conjugation techniques exist which are readily available to one skilled in the art. Commonly used enzymes include horseradish
peroxidase, glucose oxidase, B-galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production,upon hydrolysis by the corresponding enzyme, of a detectable colour change. It is also possible to employ fluorogenic substrates, which yield a fluorescent product.
Alternatively, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining ternary complex is then exposed to the light of the appropriate wavelength, the fluorescence observed indicates the presence of the hapten of interest, ϋnmunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed. It will be readily apparent to the skilled technician how to vary the procedure to suit the required purpose. It will also be apparent that the foregoing can be used to label M peptides and to use same directly in the detection of M protein antibodies.
The present invention is further described by reference to the following non-limiting Figures and Examples.
In the Figures:
Figure 1 is a graphical representation showing the proliferative response of lymph node cells from B10(A,E), B10.D2(B,F), B10.BR(C,G) and
B10.S(7R)(D,H) mice after immunization with pools of 6 peptides (A,B,C,D) or individual peptides (E,F,G,H). The peptide pools were as follows: 145-150, 151-156, 157-162. In experiments A-D, the different bars refer to separate experiments as listed below each section of the figure; in experiments E-H, the different bars refer to the different antigens used in vitro, as listed below Fig. 1H.
Figure 2 is a photographic representation of an immunoblot of porcine heart myosin (lane 1), HCl-extract M protein (lane 2) and human heart tissue protein (lane 3). Membranes were reacted against anti-porcine heart myosin antisera (A); anti-M-5 cell extract antisera (B); normal mouse serum (C); B10.BR anti-peptide 145 antisera (D); B10.BR anti-peptide 146 antisera (E); B10.D2 anti-peptide 149 sera (F); BIO anti-peptide 150 antisera (G); B10.BR antipeptide 151 antisera (H) and B10.S(7R) anti-peptide 151 antisera (1). Relative molecular masses (x10-3) are listed at the left of the Figure.
Figure 3 is a graphical representation showing mean positive optical density readings of ELISA assays of serum antibodies from (A) Caucasian and (B) Aboriginal subjects against individual peptides. See Example 2 for
abbreviations.
EXAMPLE 1
MAPPING B AND T CELL EPITOPES
1. Materials and Methods Peptides.
Fifteen overlapping peptides representing the conserved region of the M-5 protein (Miller et al, 1988), 3 peptides representing the variable amino-
terminal regions of the M-5, M-6 and M-24 proteins (Miller et al, 1988;
Hollingshead et al, 1986; Mouw et al, 1988), two peptides representing human heart myosin (Kurabayashi et al, 1988) and one peptide representing human skeletal muscle myosin (Saez et al, 1986) were synthesized by the "tea-bag" method (Hough ten, 1985). Purity was checked by HPLC. Their sequences are listed in Table 1. Peptides were dissolved in PBS at a concentration of 10 mg/ml and kept at -20C until used.
Streptococcal M-5 protein extract (Rotta, et al. 1980).
M-5 group A streptococci were cultured in 80 ml Todd-Hewitt broth with 20% v/v fetal calf serum, incubated at 37C for 16 hours. Cells were centrifuged and washed (X3) with sterile PBS pH 7.4 and resuspended in HCl pH 2. The suspension was then boiled for 10 minutes in water bath. The pH was adjusted to 7.0 by NaOH and centrifuged at 3000 rpm for 10 minutes, the supernatant was isolated and checked for sterility by dropping on blood agar plate.
Heart tissue proteins.
Porcine heart myosin and tropomyosin were purchased from Sigma Chemical Co. Human heart atrial tissue was derived from surgical specimens and were cut into small pieces and macerated in an homogenizer with cold PBS pH 7.4, centrifuged, supernatant were kept at -20C until used. Pellets were suspended in SDS-PAGE sample buffer and boiled for 5 minutes, centrifuged, and supernatants were kept at 4C for running SDS-PAGE. Human heart pericardϊal tissue was derived from surgical specimens and macerated in cold PBS pH 7.4 and centrifuged at 3000 rpm; the supernatant was isolated and kept at -20C until used.
Lymph node cell proliferation assays.
Peptides were administered subcutaneously at the tail base (either in pools of 6 or individually) to H-2 congenic mice on the B10 background [B10(H2b); B10.D2(H2d); B10. BR(H-2k); B10.S(7R)(H-2S)], with each mouse receiving 30 μg of peptide emulsified in complete Freund's adjuvant (CFA) (Difco). Ten
days later, lymph node cells were then plated in quardruplicate at 4×l05 per well in flat-bottomed microtitre plates in MEM medium containing 2% v/v heat inactivated normal mouse serum, 5×10- 5 M 2-mercaptoethanol, 20 μg gentamicin and antigen (at various concentrations). The plates were placed in a humidified 5% v/v CO2/air environment at 37C for 4 days and then each well was pulsed with 1 μCi 3[H]thymidine for 16 hrs. Incorporation of label was measured by liquid scintillation spectroscopy using a β-plate counter (LKB). A "Stimulation Index" (SI) was defined as: {cpm (in the presence of
antigen)} / {cpm (in the absence of antigen)}.
Antibody Production.
Mice were immunized subcutaneously with 30 μg of peptide emulsified in CFA. Mice were given subsequent booster injections at intervals of 10 days with 30 μg peptide dissolved in PBS for 3 boosters. Prior to boost, mice were bled via the tail artery and sera prepared and kept at -20C until used.
ELISA for determining murine antibodies.
Antigen was diluted to 5 μg/ml in carbonate-bicarbonate buffer (pH9.6) and coated onto polyvinyl chloride microplates (Flow Laboratory) in a volume of 100 μl per well overnight at room temperature. The antigen was then removed and the wells blocked with 200 μl of 2% w/v bovine serum albumin (BSA) for 1 hr at 37C. Plates were then washed 5 times with PBS-Tween 20 buffer.
Serum dilutions were prepared in 0.5% w/v BSA PBS-Tween 20 (BSA-PBS-T) buffer and incubated for 1 hr at 37C. The plates were then washed and peroxidase-conjugated goat-anti-mouse IgG (Tago Inc.) was then added at a dilution of 1:4000 in BSA-PBS-T for 1 hr at 37C. After further washing, ABTS substrate in citric acid and H2O2 was applied and incubated for 30 mins, the optical density was measured at 405 nm in an ELISA reader (Multiscan, Flow Laboratories). The lowest dilution that gave an OD of greater than 3SD above the mean OD of control wells (containing normal mouse serum at the same dilution) was defined as the titre.
ELISA for determining human antibodies.
One hundred μl of peptide at 5 μg/ml was coated on polypropylene plate (Lϊnbro, Flow) in carbonate coating buffer pH 9.6 (Na3CO3 1.9292 g, NaHCO3, 3.8052 g, distilled water 1L) and left at room temperature overnight or at 4 °C for long term storage. Antigen was discarded and wells blocked with 4% skimmed milk in PBS pH 7.4 and 0.05% Tween 20, incubated at 37 °C for 1 hr and washed 5 times. One hundred μl of serum diluted 1:40 was added and incubated at 37 °C for 1 hr. After 5 washes, one hundred μL of goat anti-human IgG at 1:3000 dilution was added and incubated at 37 °C for 1 hr, then washed 5 times with PBS pH 7.5. ABTS (2,2'-AZINO-bis- ETHYLBENZTHIAZOLINE-6-SULFONIC ACID) (Sigma) with H2O2 was added and incubated for 30 min. The reactions were measured by
spectrophotometer at 405 nm. We are confident that the peptides bound to the wells since all peptides were recognized by sera from at least one individual (titer > 50; OD > 0.5). Furthermore murine antisera raised against these many of these peptides bound the peptides in the wells at titres > 6,400 (14).
SDS-PAGE and immunoblot.
Slab gel electrophoresis (Laemmli, 1970) with modification was performed in 7% w/v acrylamide gel using the Biorad minigel apparatus. Fifteen microliter of porcine heart myosin, human heart tissue protein and M-5 protein in sample buffer (0.05 M Tris-HCl, 0.002 M EDTA, 10% y/v glycerol, 1% w/v SDS, 1% v/v mercaptoethanol and bromphenol blue) were applied to the gel and run for 45-60 minutes until the indicator bromphenol blue reached the bottom of the gel, at which time the gel was removed and blotted for 1 hr onto a nitrocellulose membrane (0.45 μm pore size) in transfer buffer. The blot was blocked with 3% w/v skim milk with 0.05% v/v Tween 20 overnight at 4C. The membrane was then added to 1:100 dilution of mouse serum containing putative antibodies for 1 hr at 37C, then 1:1000 dilution of peroxidase conjugated goat-anti-mouse IgG in 3% w/v skim milk without Tween 20 for 1 hr at 37C. Membranes were washed 5 times with PBS between steps. The
antigen bands were observed after the addition of substrate (4-chloro-1-naphthol in methanol and H2O2) for 10 min. The reaction was stopped by washing with distilled water. Bactericidal assay.
M-5 group A streptococci were cultured overnight in 1 ml Todd-Hewitt broth at 37C, centrifuged and resuspended in 10 ml skim milk broth and stored at -70C until used. Before the assay, the bacteria were thawed and diluted to 10-5 dilution in sterile normal saline. Fifty μl of the bacterial dilution was then mixed with 50 μl of mouse serum and 400 μl of normal heparinized human blood was added. The mixture was then incubated with end over end rotation at 37C for 3 hrs, and 50 μl of the mixture was diluted and spread onto blood agar plates and colonies counted after 24-48 hrs of incubation. The percentage of bacteria killed was determined by counting the number of colonies growing following incubation with test sera and comparing this with the number of colonies growing following incubation in control sera.
2. RESULTS Four different strains of mice which differ only at their MHC loci (H-2) were immunized at the tail base with groups of pooled peptides (6 peptides per pool) which overlapped the carboxylterminal conserved half of the M protein and the aminoterminal variants (Table 1, peptides 145-162). Draining lymph node cells were then challenged in vώrawith individual peptides. This protocol is designed to optimize the screening procedure for T cell epitopes. Six mice were used for each immunization and the experiments were each performed 2 or 3 times for each strain/pool combination (Figure 1 A,B,C,D). A number of possible T cell epitopes were thus identified for each strain. These peptides were then used individually to immunize mice of the appropriate strain. Lymph node cells were then challenged with the individual peptides, Purified Protein Derivative of Mycobacterium bovis (PPD) (as a positive control), tropomyosin and an extract of human pericardial heart tissue (see Example 1) (Figure 1
E,F,G,H). There were generally good responses to the specific peptides and to PPD, although not all peptides were able to reproducibly stimulate T cell responses, reflecting differences in the degrees of immunodominance of the various peptides (Gammon et al, 1987; Good et al, 1990). However, there were only minimal responses to tropomyosin and heart tissue extract. Conversely, all strains were immunized with an extract of human heart tissue and draining lymph node cells were challenged with heart tissue and the various peptides. While there was a very vigorous response to heart tissue extract (SI range: 50-123), there was no proliferation to the M protein peptides (SI all <2). To further determine the extent of any T cell cross-reactivity between the M protein and heart or muscle myosin peptides, mice were immunized with peptides from the M protein and draining lymph node cells stimulated in vitro with porcine heart myosin as well as peptides representing human heart myosin and human skeletal muscle myosin (chosen because of their sequence homology with M protein as shown in Table 2). The results are shown in Table 3. Although peptide 146-specific T cells from B10.BR mice responded to porcine myosin, the response (SI: 3.57) was much less than the response to peptide 146 (SI: 38.95). Thus, the results are consistent with there being no response or minimal response of M peptide-specific T cells with myosin antigens.
To determine whether the proiiferative T cell epitopes represented "helper" T cell epitopes, mice were immunized subcutaneously with the individual peptides emulsified in CFA, boosted with aqueous peptide (X3), and serum analysed for the presence of peptide-specific antibodies. Many peptides stimulated antibody production indicating that many of the proiiferative T cell epitopes were also helper epitopes (Table 4).
In order to determine whether T and B cells recognised the same regions of these 20-mer peptides, mice were immunized with individual peptides, and then T cells and antibodies tested for reactivity to overlapping peptides (overlap of 10 amino acids). Table 5 lists the various stimulation indices and
ELISA titres for the immunodominant epitopes. In most cases, T and B cell epitopes appeared to map to similar regions of the peptides. With respect to peptide 149 antibodies from B10JD2 mice reacted well with both peptides 148 and 149, whereas peptide 149-specific T cells respond well to peptide 149, but not at all to peptide 148.
Cross-reactivity of serum antibodies to porcine heart myosin was also
determined. In the first set of experiments, different mice were immunized with various peptides and the results of pooled or individual sera are given in Table 6 for porcine myosin-reactive antisera. Following this,
a separate set of experiments was performed (Table 7) where further mice were immunized and boosted with either peptides 149 or 151- the peptides most strongly associated with induction of anti-myosin responses in Table 6. As shown, (Tables 6 and 7), even though these mice are inbred H-2 congenic animals, differences were noted between individual animals in their ability to generate anti-myosin antibodies, although all animals in Table 7 produced antipeptide antibodies. When positive sera were confirmed with immunoblot, antibodies to peptides 145, 146, 149, 150, and 151 reacted with porcine heart myosin (Fig. 2 D-I). There was also a moderate reaction with anti-peptide 146 (B10.BR), 150 (B10), and 151 (B10.BR) antisera to human atrial tissue (Fig. 2 E,G,H). Antibody to porcine heart myosin reacted with acid-extracted M-5 protein and strongly with human heart tissue (Figure 2A), and antibody to acid extract of M-5 protein also reacted with porcine heart myosin and human atrial tissue proteins (Figure 2B).
Antibodies to the conserved peptides as well as antibodies to the type-specific aminoterminal B cell epitopes were tested for their ability to kill serotype 5 group A streptococci in a bactericidal assay (Table 8). As previously described, antibodies to peptide 160 (aminoterminal epitope from type M-5) were associated with significant killing (Beachey et al, 1988); however, the inventors were able to reproducibly show that antibodies to peptides 145.
EXAMPLE 2
MAPPING HUMAN B AND T CELL EPITOPES
1. Materials and Methods The following abbreviations are used below and in Figure 3.
ARFA, Aborigines with acute rheumatic fever (RF) (n = 6);
RHDA, Aborigines with rheumatic heart disease as a result of prior RF
(N = 23);
PARFA, Aborigines having a past history of RF, but not having any present clinical evidence of rheumatic heart disease (N=6);
CHOREAA, Aborigines with previous rheumatic chorea without rheumatic heart disease (N= 1);
CRHDA, Aborigines with both past rheumatic chorea and rheumatic heart disease (N = 3);
HEARTA, Aborigines having other (non-rheumatic) forms of heart disease
(N = 15);
NORMALA, Aborigines having no history of heart disease (N=32);
PARFC, Caucasians having a past history of RF, but not having any present clinical evidence of heart disease (N=27);
HEARTC, Caucasians having other (non-rheumatic) forms of heart disease
(N=23);
NORMALC, Caucasians having no history of heart disease (N=28).
Patients were assessed by a specialist physician. Those with rheumatoid heart disease (RHD) had unequivocal clinical evidence of established significant mitral + /- aortic valve damage, confirmed by echocardiogram in the majority of cases. Those with primary or recurrent rheumatic fever (RF) fulfilled the revised Jones criteria for diagnosis of RF. (Special Committee Report, Jones criteria revised for guidance in the diagnosis of Rheumatic Fever, Circulation publication 62; 203A-208A, 1984). A small number of patients also manifested classical rheumatic chorea. All controls were examined and found to have no clinical evidence of RHD in addition to having no past history of RF.
Antigens.
Overlapping synthetic peptides spanning the conserved region of the M 5 protein were produced as described in Example 1. Human heart pericardial tissue was derived from surgical specimens as described in Example 1.
Lymphocyte proliferation assays.
Twenty five millilitres of blood were drawn. Peripheral blood mononuclear cells (PBM) were prepared by layering blood diluted in an equal volume of MEM over Ficoll-paque, centrifuging at 400 g for 25 min, and collecting the buoyant cells. Cells were washed, counted and added to round-bottomed microtiter wells at a concentration of 200,000 cells per well in MEM medium containing 10% v/v normal human serum, and gentamicin (20 μg/ml). Some wells contained peptide at optimal concentration (30 μg/well), whereas other wells without peptide were used as control wells. After 6 days, wells were pulsed with 0.25 μCi of 3H-methyl thymidine, and 16 hrs later, wells were harvested onto filter paper and thymidine incorporation estimated by liquid scintillation spectroscopy using an LKB beta-plate system. The mean counts per minute (CPM) of wells with peptide was divided by the mean CPM of wells without peptide to give a stimulation index (SI).
Serum isolation.
Three millilitres of blood were put in a sterile tube and let stand at room temperature for 3-4 hours. The serum was isolated by centrifugation and stored at -20°C.
T cell line generation.
The method is generally as described in Good el al (1987). The peripheral blood lymphocytes from a donor (GL) were stimulated with 150 μg/ml of HCl extracted M protein in vitro and incubated at 37 ºC in 5% v/v CO2 atmosphere for 6 days. Aliquols of 30 units/ml of r-lL-2 was then added for 7-10 days and the cells were stimulated again with the same amount of peptide with 4 × 106 autologous PBMC without IL-2. After further expansion with IL-2 for 10-14
days, the lines were assayed.
Phenotypic analysis of T cell lines.
Cells were washed three times with PBS supplemented with 9% w/v BSA, 0.1% w/v sodium azide (Sigma) (PBS-BSA-Na) and resuspended at 106/ml in the same buffer in microtiter plate with optimal dilutions of monoclonal antibodies. After three washes in cold PBS-BSA-Na, 50 μl of 1/200 dilution of a fluoresceinated goat anti-mouse IgG (Tago, Burlingame, CA) was added and the cells incubated at 4 °C in the dark for 30 min. After three additional washes, cells were resuspended in 200 μl PBS with 1% v/v par aform aldehyde and flow microfluorometry was performed on a fluorescence-activated cell sorter (FACS) and analyzed by LYSIS II cell analysis program.
Cytotoxicity assays.
The method is generally as described in Doolan el aL (1991), Autologous PBM were stimulated with 3 μg/ml PHA in MEM supplemented with 10% v/v normal human serum for 3 days and 30 U/ml of IL-2. The PHA blasts were rested for 3 days then washed 3 times and labelled for 1 hr at 37 °C with 100 μCi of 51Cr, with or without 10 μg/ml of peptide 145, 146 or M protein. After three washes, 5000 51Cr-labeled target cells were added to 96-well round bottom plate with varying number of effector cell lines at 100, 80, 40, 20, 10, 5, 2.5 and 1.25 ratios of effector-to-target (E/T) cells. Cells were incubated at 37 °C for 6 hours. After the incubation, plates were centrifuged at 100 μl of supernatants were harvested at 51Cr release was measured with a gamma counter. Maximum release was measured after detergent lysis. Percent specific lysis was calculated as the following formula:
2. Results The overlapping synthetic peptides (20-mers) spanning the conserved
carboxylterminal region of the M protein were used to define B and T cell epitopes in Aboriginal donors comprising patients with histories of RF, RHD, other heart diseases (mainly ischaemic) and normal controls, and Caucasian donors comprising those with past histories of RF, other heart diseases (mainly ischaemic) and normal controls.
B Cell Epitope Mapping.
Sera from the different individuals were assayed by ELISA for the presence of antibodies specific for the overlapping peptides. The sera were diluted 1:40 and added to wells to which peptides were attached. The mean optical densities for sera from different groups of Aborigines and Caucasians are given in Figure 3. Population-specific differences were observed. However, a striking feature is that all groups of Aborigines (patients and controls) have antibodies that predominantly recognize peptide 145. There was a much lower response to the overlapping peptide 146, thus mapping a dominant linear B cell epitope to the aminoterminal half of peptide 145.
T Cell Epitope Mapping.
T cell epitopes were defined using the lymphoproliferation assay. Initially, the reactivity to the peptides of cord blood lymphocytes of 17 healthy Caucasian neonates born from healthy mothers was tested. Since the highest stimulation index recorded was 5, this value was used as a cutoff for the proliferation studies for the adult subjects. Amongst Caucasians, individuals with past history of RF responded more frequently than individuals with no history of RF. The peptide most frequently recognized by this group was peptide 145 (25% of individuals). Surprisingly, however, T cells from 10-25% of individuals
with other heart diseases (predominantly ischaemic heart disease) also responded to many peptides.
Amongst Aborigines, T cells from patients with past histories of RF or RHD responded more frequently than T cells from normal control subjects or patients with other heart diseases. Peptides 145, 147, 152 and 157 (in normal controls) were recognized by >20% of the population studied. Within the Aboriginal group, there was no significant difference in the peptide-specific T cell responses of patients with established RHD and those with past or present histories of RF.
Because of the potential importance of peptide 145 in developing a vaccine, T cell lines specific for peptides 145 and 146, and for an acid extract of serotype 5 M protein were generated. The donor was a normal Caucasian individual with no history of heart disease. All lines responded to both peptides 145 and 146, including the M protein-specific line which responded to both the peptides and to the M protein extract at equivalent levels. This confirms that in this individual, the T cell epitope is represented by the overlapping segment of these peptides (AKKQVEKALE), and that this epitope is the dominant epitope within the protein. Surface phenotype analysis of the lines showed that most cells expressed CD3+, CD8 +, and TCRα/ β+, whereas most cells expressed neither CD4 nor TCRγ/δ. The T cell lines were tested for reactivity to porcine myosin and an extract of human heart, but there was minimal reactivity. Functional analysis of these lines showed that the peptide 146-specific line was cytotoxic, being able to kill autologous PHA-stimulated T cell blasts in the presence of the peptide. Although this was a repeated finding for this line, much less cytotoxicity was observed for the other lines. Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations
and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.
Table 1. Overlapping peptides representing the conserved region (145-159) of M-5, aminoterminal regions of M-5, M-6 and M-24 group A streptococci (160, 161 and 162, respectively), human skeletal muscle myosin (164) and human heart myosin (165 and 166).
Table 2. Amino acid sequence homology between peptides derived from M-5 protein conserved re ion and human skeletal muscle 164 or human heart m osin e tides 165-166
Table 3. Lack of T cells cross-reactivity of M peptide-specific T cells with porcine heart myosin, human heart myosin peptides, and skeletal muscle myosin peptides.
Table 4. T cell and antibody responses of mice after immunization with individual peptides
3
CO
to O
i
Table 7. Cross-reactivity of M peptide-specific antibodies with procine heart myosin
REFERENCES:
Ayakawa, G.Y., A.S. Bleiweis, P.J. Crowley, and M.W. Cunningham, 1988. J. Immunol. 140: 253.
Beachey, E.H., Bronze, M., Dale, J.B. Kraus, W. Poerier, T., and Sargent, S., 1988. Vaccine 6: 192.
Cunningham, M.W., and Rusell, S.M. 1983. Infect, Immun. 42: 531.
Cunningham, M.W., Hall, N.K., Krisher, K.K. and Spanier, A.M. 1986. J. Immunol. 136: 293.
Cunningham, M.W., McCormack, J.M., Talaber, L.R., Harley, J.B., Ayoub, E.M., Muneer, R.S., Chun, L.T., and Reddy, D.V. 1988. J. Immunol. 141 : 2760.
Dale, J.B., Beachey, E.H. 1986. J. Exp. Med. 164: 1785.
Doolan, D.L. et aL 1991. Int. Immunol. 3: 511-516.
Fenderson, P.G. Fischetti, V.A., and Cunningham, M.W. 1989. J.
Immunol 142: 2475.
Gammon, G., Shastrϊ, N., Gogswel, J., Wilbur, S., Sadegh-Nasseri, S., Kryzch, U. Miller, A., and Sercarz, E., 1987. Immunol. Rev. 98: 53.
Good, M.F., Branigan, J., Smith, G., and Houghten, R.A. 1990. Peptide Research 3: 110.
Good, M.F. et al. 1987. J. Immunol. 138: 306-311.
Hollingshead, S.K., Fischetti, V.A. and Scott, J.R. 1986. J. Biol. Chem 261; 1677.
Houghten, R. A. 1985. Proc. Natl. Acad. Sci. USA 82: 5131.
Kaplan, E.L., Johnson, DJ. and Cleary, P.P. 1989. J. Infect. Pis.
159:101.
Kurabayashi, M., Tsuchimochi, H., Komura, I., Takaku, F., and Yazaki, Y. 1988. J, Clin, Invest. 82:524.
Laemmli, U.K. 1970. Nature. 277:680.
Miller, L., Gray, L., Beachey, E.H. and Kehoe, M. 1988. .J. Binl. Chem. 266:5668.
Mouw, A.R., Beachey, E.H., and Burdett, V. 1988. J. Bacteriol. 170:676.
Rotta, J. and Facklam, R.R. 1980. Manual of Microbiological
Diagnostic Methods for Stretococcal Infections and Their Sequelae. World Health Organisation.
Saez, L. and Leinwand, LA. 1986. Nucleic Acid Res. 14:2961.
Tarn. 1988. Proc. Natl. Acad. Sci. USA 85: 5409.
Claims
1. A synthetic peptide comprising at least one B cell epitope from the carboxyterminus of M protein of Group A β-hemolytic streptococci wherein an antibody reactive to the B cell epitope is only minimally reactive to human heart tissue.
2. A synthetic peptide according to claim 1 further comprising at least one T cell epitope from the carboxyterminus of M protein and /or from an extraneous part of, or a fusion molecule with, the synthetic peptide.
3. A synthetic peptide according to claim 1 or 2 when produced by recombinant means.
4. A synthetic peptide according to claim 1 or 2 when produced by chemically synthetic means.
5. A synthetic peptide according to claim 1 or 2 comprising an amino acid sequence substantially derived from the conserved region of the M protein or single or multiple amino acid substitutions, deletions and /or additions therein or chemical analogues thereof.
6. A synthetic peptide according to claim 5 wherein the amino acid sequence is derived from amino acid residues 337 to 492 of type 5 M protein or a single or multiple amino acid substitutions, deletions and/or additions therein or chemical analogues thereof.
7. A synthetic peptide according to claim 6 having the amino acid sequence:
L R R D L D A S R E A K K Q V E K A L E
8. A method for vaccinating a human subject against streptococcal infection comprising administering to said subject a humoral immunity developing effective amount of a peptide comprising at least one B cell epitope from the M protein of Group A β-hemolytic streptococci and at least one T cell epitope, wherein an antibody reactive with the B cell epitope is only minimally reactive with heart tissue, for a time and under conditions sufficient for said immunity to develop.
9. A method according to claim 8 wherein the T cell epitope is from the M protein carboxyterminus.
10. A method according to claim 8 wherein the T cell epitope is from an extraneous part of or fusion molecule with, the synthetic peptide.
11. A method according to claim 8 or 10 or 11 wherein the synthetic peptide is produced by recombinant means.
12. A method according to claim 8 or 9 or 10 wherein the synthetic peptide is produced by chemically synthetic means.
13. A method according to claim 8 or 9 or 10 wherein the synthetic peptide comprises an amino acid sequence substantially derived from the conserved region of the M protein or single or multiple amino acid substitutions, deletions and/or additions therein or chemical analogues thereof.
14. A method according to claim 13 wherein the amino acid sequence is derived from amino acid residues 337 to 492 of type 5 M protein or a single or multiple amino acid substitutions, deletions and/or additions therein or chemical analogues thereof.
15. A method according to claim 14 wherein the synthetic peptide
comprises the amino acid sequence:
L R R D L D A S R E A K K Q V E K A L E
16. A vaccine for developing humoral immunity to M protein in a human said vaccine comprising a peptide carrying at least one B cell epitope from the M protein and at least one T cell epitope wherein an antibody reactive with said B cell epitope is only minimally reactive with heart tissue, said vaccine further comprising one or more pharmaceutically acceptable carriers and/or diluents.
17. A vaccine according to claim 16 wherein the T cell epitope is from the M protein carboxyterminus.
18. A vaccine according to claim 16 wherein the T cell epitope is from an extraneous part of, or fusion molecule with, the synthetic peptide.
19. A vaccine according to claim 16, 17 or 18 wherein the synthetic peptide is produced by recombinant means.
20. A vaccine according to claim 16, 17 or 18 wherein the synthetic peptide is produced by chemically synthetic means.
21. A vaccine according to claim 16 wherein the synthetic peptide comprises an amino acid sequence substantially derived from the conserved region of the M protein or single or multiple amino acid substitutions, deletions and/or additions therein or chemical analogues thereof.
22. A vaccine according to claim 21 wherein the synthetic peptide comprises an amino acid sequence derived from amino acid residues 337 to 492 of type 5 M protein or a single or multiple amino acid substitutions, deletions and/or additions therein or chemical analogues thereof.
23. A vaccine according to claim 22 wherein the synthetic peptide comprises the amino acid sequence:
L R R D L D A S R E A K K Q V E K A L E
24. An antibody capable of binding to a synthetic peptide comprising at least one B cell epitope from the carboxyterminus of M protein of Group A β-hemolytic streptococci, wherein said antibody is only minimally reactive to human heart tissue.
25. An antibody according to claim 24 wherein said antibody is polyclonal.
26. An antibody according to claim 24 wherein said antibody is monoclonal.
27. An antibody according to claim 24 or 25 or 26 wherein the synthetic peptide comprises the amino acid sequence:
L R R D L D A S R E A K K Q V E K A L E
28. A method for the diagnosis of streptococcal infection in a subject comprising contacting a biological sample from said subject with an antibody binding effective amount of a synthetic peptide according to any one of claims 1 to 8 for a time and under conditions sufficient for an antibody-synthetic peptide complex to form and then detecting said complex.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU37417/93A AU3741793A (en) | 1992-04-08 | 1993-03-30 | Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPL180092 | 1992-04-08 | ||
AUPL1800 | 1992-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993021220A1 true WO1993021220A1 (en) | 1993-10-28 |
Family
ID=3776079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1993/000131 WO1993021220A1 (en) | 1992-04-08 | 1993-03-30 | Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1993021220A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0618813A1 (en) * | 1992-09-16 | 1994-10-12 | The University Of Tennessee Research Corporation | Antigen of hybrid m protein and carrier for group a streptococcal vaccine |
EP0625043A1 (en) * | 1992-09-16 | 1994-11-23 | The University Of Tennessee Research Corporation | Recombinant multivalent m protein vaccine |
WO1997026008A1 (en) * | 1996-01-22 | 1997-07-24 | Regents Of The University Of Minnesota | STREPTOCOCCAL C5a PEPTIDASE VACCINE |
EP0787139A1 (en) * | 1994-10-14 | 1997-08-06 | The Council Of The Queensland Institute Of Medical Research | Synthetic peptides and vaccines comprising same |
EP0837130A2 (en) * | 1996-09-24 | 1998-04-22 | Smithkline Beecham Corporation | M protein analogue from Streptococcus pneumoniae |
US6355255B1 (en) | 1998-12-07 | 2002-03-12 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US7255867B2 (en) * | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
US7256265B2 (en) | 1999-12-03 | 2007-08-14 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US8563001B2 (en) | 2008-11-05 | 2013-10-22 | Regents Of The University Of Minnesota | Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3426889A (en) * | 1988-03-25 | 1989-10-16 | Rockefeller University, The | Synthetic peptides from streptococcal m protein and vaccines prepared therefrom |
WO1990015872A1 (en) * | 1989-06-21 | 1990-12-27 | The Rockefeller University | Recombinant poxvirus and streptococcal m protein vaccine |
-
1993
- 1993-03-30 WO PCT/AU1993/000131 patent/WO1993021220A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3426889A (en) * | 1988-03-25 | 1989-10-16 | Rockefeller University, The | Synthetic peptides from streptococcal m protein and vaccines prepared therefrom |
WO1990015872A1 (en) * | 1989-06-21 | 1990-12-27 | The Rockefeller University | Recombinant poxvirus and streptococcal m protein vaccine |
Non-Patent Citations (1)
Title |
---|
INFECTION AND IMMUNITY, Volume 59, No. 12, issued December 1991, J.H. ROBINSON et al., "Mapping T-Cell Epitopes in Group A Streptococcal Type 5M Protein ", pages 4324-4331. * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0625043A1 (en) * | 1992-09-16 | 1994-11-23 | The University Of Tennessee Research Corporation | Recombinant multivalent m protein vaccine |
EP0625043A4 (en) * | 1992-09-16 | 1997-05-21 | Univ Tennessee Res Corp | Recombinant multivalent m protein vaccine. |
EP0618813A4 (en) * | 1992-09-16 | 1997-05-21 | Univ Tennessee Res Corp | Antigen of hybrid m protein and carrier for group a streptococcal vaccine. |
EP0618813A1 (en) * | 1992-09-16 | 1994-10-12 | The University Of Tennessee Research Corporation | Antigen of hybrid m protein and carrier for group a streptococcal vaccine |
US6174528B1 (en) | 1994-10-14 | 2001-01-16 | Counsel Of The Queensland Institute Of Medical Research | Synthetic peptides and vaccines comprising same |
EP0787139A4 (en) * | 1994-10-14 | 2002-10-09 | Queensland Inst Med Res | Synthetic peptides and vaccines comprising same |
EP0787139A1 (en) * | 1994-10-14 | 1997-08-06 | The Council Of The Queensland Institute Of Medical Research | Synthetic peptides and vaccines comprising same |
US6270775B1 (en) | 1996-01-22 | 2001-08-07 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US7635483B2 (en) | 1996-01-22 | 2009-12-22 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US5846547A (en) * | 1996-01-22 | 1998-12-08 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US8440205B2 (en) | 1996-01-22 | 2013-05-14 | Regents Of The University Of Minnesota | Streptococcal C5A peptidase vaccine |
US6951653B2 (en) | 1996-01-22 | 2005-10-04 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
WO1997026008A1 (en) * | 1996-01-22 | 1997-07-24 | Regents Of The University Of Minnesota | STREPTOCOCCAL C5a PEPTIDASE VACCINE |
US6358704B1 (en) | 1996-09-24 | 2002-03-19 | Smithkline Beecham Corporation | M protein |
EP0837130A3 (en) * | 1996-09-24 | 1999-11-03 | Smithkline Beecham Corporation | M protein analogue from Streptococcus pneumoniae |
EP0837130A2 (en) * | 1996-09-24 | 1998-04-22 | Smithkline Beecham Corporation | M protein analogue from Streptococcus pneumoniae |
US6355255B1 (en) | 1998-12-07 | 2002-03-12 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US7256265B2 (en) | 1999-12-03 | 2007-08-14 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US7255867B2 (en) * | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
US8563001B2 (en) | 2008-11-05 | 2013-10-22 | Regents Of The University Of Minnesota | Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease |
US9127050B2 (en) | 2008-11-05 | 2015-09-08 | Regents Of The University Of Minnesota | Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5154923A (en) | Polypeptides and derivatives thereof as well as their use in pharmaceutical and diagnostic compositions | |
JP3771265B2 (en) | Moraxella high molecular weight major outer membrane protein | |
Dale et al. | Sequence of myosin-crossreactive epitopes of streptococcal M protein. | |
JP2907552B2 (en) | Haemophilus outer membrane protein | |
Pruksakorn et al. | Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. | |
US5620862A (en) | Methods for diagnosing early Lyme disease | |
US6174528B1 (en) | Synthetic peptides and vaccines comprising same | |
JPH09505723A (en) | Immunoreactive peptide sequence from 43KD human cancer antigen | |
WO2000023595A1 (en) | Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof | |
US5656451A (en) | OspE, OspF, and S1 polypeptides in borrelia burgdorferi | |
Smulian et al. | Immunization with recombinant Pneumocystis carinii p55 antigen provides partial protection against infection: characterization of epitope recognition associated with immunization | |
JP2000507232A (en) | Vaccine compositions and methods useful for inducing immune protection against arthritogenic peptides required for the pathogenesis of rheumatoid arthritis | |
US6172192B1 (en) | Toxoplasma gondii antigen Tg20 | |
CA2112466A1 (en) | Methods and compositions for diagnosing lyme disease | |
WO1993021220A1 (en) | Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection | |
US7786260B1 (en) | Polypeptide fragments comprising c terminal portion of helicobacter catalase | |
US7108858B2 (en) | Non-anaphylactic forms of allergens and their use | |
US20090162369A1 (en) | Synthetic chimeric peptides | |
WO2002089733A2 (en) | Recombinant orf2 proteins of the swine hepatitis e virus and their use as a vaccine and as a diagnostic reagent for medical and veterinary applications | |
WO1993011157A1 (en) | MALARIAL VACCINE AND PEPTIDES COMPRISING HUMAN T-CELL EPITOPE OF CIRCUMSPOROZOITE PROTEIN OF $i(P.VIVAX) | |
JPH10201484A (en) | New ftsl | |
WO2003064446A2 (en) | Plasma protein-binding peptides from bacterial curli | |
KR100216390B1 (en) | Haemophilus outer membrane protein | |
AU772513B2 (en) | Polypeptide fragments comprising C-terminal portion of helicobacter catalase | |
CA2253834A1 (en) | B. burgdorferi polypeptides expressed in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA KR NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |